- Home
- SYNX vs BIAF Comparison
SYNX vs BIAF Comparison
Compare SYNX & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYNX
- BIAF
- Stock Information
- Founded
- SYNX 2005
- BIAF 2014
- Country
- SYNX Israel
- BIAF United States
- Employees
- SYNX N/A
- BIAF N/A
- Industry
- SYNX
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SYNX
- BIAF Health Care
- Exchange
- SYNX Nasdaq
- BIAF Nasdaq
- Market Cap
- SYNX 13.7M
- BIAF 12.2M
- IPO Year
- SYNX 2024
- BIAF 2022
- Fundamental
- Price
- SYNX $1.74
- BIAF $0.30
- Analyst Decision
- SYNX
- BIAF Hold
- Analyst Count
- SYNX 0
- BIAF 1
- Target Price
- SYNX N/A
- BIAF N/A
- AVG Volume (30 Days)
- SYNX 127.8K
- BIAF 11.2M
- Earning Date
- SYNX 05-14-2025
- BIAF 08-13-2025
- Dividend Yield
- SYNX N/A
- BIAF N/A
- EPS Growth
- SYNX N/A
- BIAF N/A
- EPS
- SYNX N/A
- BIAF N/A
- Revenue
- SYNX $9,094,000.00
- BIAF $8,809,228.00
- Revenue This Year
- SYNX $32.35
- BIAF N/A
- Revenue Next Year
- SYNX N/A
- BIAF $20.00
- P/E Ratio
- SYNX N/A
- BIAF N/A
- Revenue Growth
- SYNX 19.14
- BIAF 78.40
- 52 Week Low
- SYNX $1.65
- BIAF $0.16
- 52 Week High
- SYNX $6.49
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- SYNX 48.15
- BIAF 50.96
- Support Level
- SYNX $1.67
- BIAF $0.22
- Resistance Level
- SYNX $1.91
- BIAF $0.46
- Average True Range (ATR)
- SYNX 0.20
- BIAF 0.04
- MACD
- SYNX 0.02
- BIAF 0.01
- Stochastic Oscillator
- SYNX 22.21
- BIAF 30.51
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.